Elvis Paćelat outlines some lessons from big pharma as medical device manufacturers succumb to new reporting obligations.
Elvis Pacelat
Advertisement
Elvis Pacelat, is VP of Compliance Solutions at AMPLEXOR Life Scienceswww.amplexor.com
Articles by Elvis Pacelat
However conservative and heavily regulated the drugs business, it too must transform itself to exploit digital opportunities - if only to ward off disruption, says Elvis Paćelat.
Advertisement
Latest Updated Articles
Pharma Must Embrace Digital TransformationPublished: November 29th 2016 | Updated:
The Great Life Sciences Regulatory RedressPublished: April 24th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
2
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
3
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
